

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO COOPERATIVE DEVELOPMENT AGREEMENT
FOR FULLY HUMAN ANTIBODY DRUGS**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (“**Nanjing Chia Tai Tianqing**”), a subsidiary of the Company, has entered into a cooperative development agreement for fully human antibody drugs with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“**Biocytogen**”) to jointly develop fully human antibody drugs for their mutually selected targets. According to this agreement, Nanjing Chia Tai Tianqing’s three leading platforms of research and development, preparations and active pharmaceutical ingredients will be integrated with Biocytogen’s self-developed fully human antibody RenMab platform with self-owned intellectual property rights and its unique full-chain development system for new drugs to jointly develop fully human antibody drugs for targets mutually selected by both parties. By leveraging Nanjing Chia Tai Tianqing’s advanced clinical development and strong manufacturing and sales capabilities and Biocytogen’s strengths in large-scale fully human antibody discovery and screening, both parties are able to advance the development of drugs for selected targets together for the earlier launch of the drugs and the benefit of patients.

The Group has extensive research capabilities with strong commercialisation capabilities. Biocytogen’s RenMab platform can rapidly generate fully human antibodies with high affinity, specificity and diversity, and its ongoing “RenMice™ HiTS Platform” programme is able to obtain a large number of candidate antibodies with high efficacy and safety through high-throughput screening and evidence-based in vivo drug efficacy screening. Through this cooperation, the Group expects to fully leverage the advantages of the respective platforms of both parties to accelerate the research and development and commercialisation of new drugs to meet the unmet clinical needs for the benefit of patients.

About Biocytogen

Biocytogen is an innovative technology-driven biopharmaceutical company headquartered in Beijing with branches in Haimen, Jiangsu, Boston, the United States, and Shanghai. Centered around its fully human antibody RenMice platform (RenMab and RenLite mice) with self-owned intellectual property rights, Biocytogen is developing and implementing a large-scale antibody development programme based on in vivo efficacy to develop antibodies for over 1,000 potential drug targets. At present, Biocytogen has entered into strategic and project cooperation agreements with a number of pharmaceutical companies in both China and overseas.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.